Strong commercial momentum builds ahead of a major pipeline test
- ACADIA has two approved drugs: NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome.
- In Q2 2026, NUPLAZID net sales were $183 million and DAYBUE net sales were $125 million.
- DAYBUE grew 30 percent year over year in the second quarter, helped by the new STIX powder form.
- A June 2026 positive CHMP opinion opened the door for a European launch of DAYBUE starting in Germany.
- The biggest pipeline test is ACP-204 in Alzheimer's disease psychosis, with Phase 2 results expected by October 2026.
- Finn scores point to a decent business with good financial health, but not a cheap stock.
Two drugs, one big readout
ACADIA sells two FDA-approved medicines and uses that cash to fund more CNS drug work. Q2 2026 showed why the setup is interesting. DAYBUE had $125 million of net sales and grew 30 percent year over year, driven by strong early demand for DAYBUE STIX. Management raised the full-year 2026 sales outlook for DAYBUE based on this momentum.
NUPLAZID is the steadier part of the story. It had $183 million of Q2 2026 net sales, growing 10 percent year over year. The temporary patient refill lag seen early in the year has completely resolved, putting the drug back on a reliable growth track.
The Europe question for DAYBUE improved after the CHMP gave the drug a positive opinion in June 2026 following a re-examination. That cleared a major overhang and set up a planned launch in Germany for the fourth quarter.
The main swing factor is ACP-204, also called remlifanserin, in Alzheimer's disease psychosis. Top-line Phase 2 results are expected in September or October 2026. A strong result could open a large market. A weak result would leave ACADIA much more dependent on NUPLAZID and DAYBUE for long-term growth.
Sales fund the science
ACADIA makes money by selling prescription drugs. NUPLAZID treats hallucinations and delusions linked to Parkinson's disease psychosis. DAYBUE treats Rett syndrome, a rare brain and development disorder.
This model is healthier than many biotech models because the company is commercial stage, cash-flow positive, and has no debt in the internal view. That means its existing products can help pay for research instead of relying only on new stock sales or borrowing.
The weak point is concentration. All product revenue comes from two medicines. If DAYBUE use slows, NUPLAZID loses exclusivity earlier than hoped, or ACP-204 fails, the long-term growth story gets thinner fast.
Valuation also matters. The business is better funded than many biotech peers, but Finn valuation scores are modest, so investors are already paying for part of the good news.
What ACADIA sells and studies
NUPLAZID
NUPLAZID is approved in the U.S. for hallucinations and delusions tied to Parkinson's disease psychosis. It is the mature profit engine, with sales rebounding strongly in Q2 2026.
DAYBUE
DAYBUE is the first FDA-approved treatment for Rett syndrome. Q2 2026 net sales were $125 million, as the new STIX powder form continues to help adoption.
Daybu in Europe
Daybu received a positive CHMP opinion in June 2026 after an earlier negative process. This sets up a planned launch in Germany during the fourth quarter of 2026.
ACP-204
ACP-204 is a next-generation 5HT2A compound being tested in Alzheimer's disease psychosis. The September to October 2026 Phase 2 readout is the biggest near-term pipeline event.
ACP-711
ACP-711 is a potential first-in-class GABA-Alpha-3 positive allosteric modulator for essential tremor. A Phase 2 study is delayed slightly to explore higher dosing, expected to begin in 2027.
ACP-271
ACP-271 is a GPR88 agonist progressing through Phase 1 trials.
ACP-101
ACP-101 was once a Phase 3 candidate for Prader-Willi syndrome. Development was stopped in September 2025, so it is no longer a growth driver.
Revenue is all product sales
ACADIA reports as one operating segment, but Q2 2026 product sales were split between NUPLAZID and DAYBUE. The mix below uses Q2 2026 net product sales of $183 million for NUPLAZID and $125 million for DAYBUE.
What could break the thesis
ACP-204 misses in Alzheimer's disease psychosis
High impact · Medium oddsThe pipeline is now heavily tied to ACP-204. A weak Phase 2 result would remove the largest near-term value creation chance and make the company look more like a two-product commercial biotech.
DAYBUE STIX persistency issues
High impact · Medium oddsGrowth is increasingly driven by DAYBUE STIX uptake, bringing back discontinued patients. The key question is whether that demand continues or fades over time.
EU commercial execution struggles
Medium impact · Medium oddsThe positive CHMP opinion lowered regulatory risk for Daybu in Europe, but the focus shifts to commercial launch. Pricing and reimbursement negotiations, starting in Germany, can slow revenue.
NUPLAZID exclusivity and pricing pressure
Medium impact · Medium oddsNUPLAZID could face Medicare price negotiation as early as 2029, and uncertainty remains around a potential six-month pediatric exclusivity extension.
In one breath
What does ACADIA Pharmaceuticals do?
ACADIA develops and sells drugs for central nervous system disorders. Its main products are NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome.
Why does DAYBUE STIX matter?
DAYBUE STIX is a powder form of DAYBUE. Management said early uptake was strong, which is helping new patients start treatment and some former patients restart.
What is the biggest ACADIA catalyst in 2026?
The biggest clinical catalyst is the ACP-204 Phase 2 readout in Alzheimer's disease psychosis, expected in September or October 2026. A positive result could change the long-term growth outlook.
Is ACADIA profitable?
The internal company view describes ACADIA as cash-flow positive with no debt. That gives it more flexibility than many biotechs, but the business still depends on two products and clinical trial success.
